111 related articles for article (PubMed ID: 32590270)
1. Desmoid-type fibromatosis: Tumour response assessment using magnetic resonance imaging signal and size criteria.
Zhu HC; Li XT; Ji WY; Li S; Sun YS
Clin Imaging; 2020 Dec; 68():111-120. PubMed ID: 32590270
[TBL] [Abstract][Full Text] [Related]
2. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging patterns of tumor response to chemotherapy in desmoid-type fibromatosis.
Zanchetta E; Ciniselli CM; Bardelli A; Colombo C; Stacchiotti S; Baldi GG; Provenzano S; Bertulli R; Bini F; Casale A; Greco FG; Ferrari A; Verderio P; Fiore M; Gronchi A; Casali PG; Morosi C; Palassini E
Cancer Med; 2021 Jul; 10(13):4356-4365. PubMed ID: 34102009
[TBL] [Abstract][Full Text] [Related]
4. MRI Volumetrics and Image Texture Analysis in Assessing Systemic Treatment Response in Extra-Abdominal Desmoid Fibromatosis.
Subhawong TK; Feister K; Sweet K; Alperin N; Kwon D; Rosenberg A; Trent J; Wilky BA
Radiol Imaging Cancer; 2021 Jul; 3(4):e210016. PubMed ID: 34213370
[TBL] [Abstract][Full Text] [Related]
5. Correlation between tumor growth and hormonal therapy with MR signal characteristics of desmoid-type fibromatosis: A preliminary study.
Gondim Teixeira PA; Chanson A; Verhaeghe JL; Lecocq S; Louis M; Hossu G; Blum A
Diagn Interv Imaging; 2019 Jan; 100(1):47-55. PubMed ID: 30037746
[TBL] [Abstract][Full Text] [Related]
6. Desmoid fibromatosis: MRI features of response to systemic therapy.
Sheth PJ; Del Moral S; Wilky BA; Trent JC; Cohen J; Rosenberg AE; Temple HT; Subhawong TK
Skeletal Radiol; 2016 Oct; 45(10):1365-73. PubMed ID: 27502790
[TBL] [Abstract][Full Text] [Related]
7. MRI characteristics predict the efficacy of meloxicam treatment in patients with desmoid-type fibromatosis.
Shimizu K; Hamada S; Sakai T; Ito S; Urakawa H; Arai E; Ikuta K; Koike H; Ishiguro N; Nishida Y
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):751-757. PubMed ID: 31448875
[TBL] [Abstract][Full Text] [Related]
8. MRI diagnosis and follow-up of chest wall and breast desmoid tumours in patients with a history of oncologic breast surgery and silicone implants: A pictorial report.
Grubstein A; Rapson Y; Zer A; Gadiel I; Atar E; Morgenstern S; Gutman H
J Med Imaging Radiat Oncol; 2019 Feb; 63(1):47-53. PubMed ID: 30443994
[TBL] [Abstract][Full Text] [Related]
9. Evidence-based MR imaging follow-up strategy for desmoid-type fibromatosis.
Gondim Teixeira PA; Biouichi H; Abou Arab W; Rios M; Sirveaux F; Hossu G; Blum A
Eur Radiol; 2020 Feb; 30(2):895-902. PubMed ID: 31468156
[TBL] [Abstract][Full Text] [Related]
10. Progressive Desmoid Tumor: Radiomics Compared With Conventional Response Criteria for Predicting Progression During Systemic Therapy-A Multicenter Study by the French Sarcoma Group.
Crombé A; Kind M; Ray-Coquard I; Isambert N; Chevreau C; André T; Lebbe C; Cesne AL; Bompas E; Piperno-Neumann S; Saada E; Bouhamama A; Blay JY; Italiano A;
AJR Am J Roentgenol; 2020 Dec; 215(6):1539-1548. PubMed ID: 32991215
[No Abstract] [Full Text] [Related]
11. MRI T1 Contrast-Enhanced Signal Intensity Is a Prognostic Indicator of Imatinib Therapy in Desmoid-Type Fibromatosis.
Zhu HC; Xu SX; Li XT; Guan Z; Li S; Sun YS
Front Oncol; 2021; 11():615986. PubMed ID: 33854962
[TBL] [Abstract][Full Text] [Related]
12. Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998).
Keus RB; Nout RA; Blay JY; de Jong JM; Hennig I; Saran F; Hartmann JT; Sunyach MP; Gwyther SJ; Ouali M; Kirkpatrick A; Poortmans PM; Hogendoorn PCW; van der Graaf WTA
Ann Oncol; 2013 Oct; 24(10):2672-2676. PubMed ID: 23868907
[TBL] [Abstract][Full Text] [Related]
13. [Magnetic resonance imaging of desmoid-type fibromatosis: Current evaluation criteria].
Ben Haj Amor M; Ploton L; Ceugnart L; Taïeb S
Bull Cancer; 2020 Mar; 107(3):359-363. PubMed ID: 32008700
[TBL] [Abstract][Full Text] [Related]
14. MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results.
Souza FF; D'Amato G; Jonczak EE; Costa P; Trent JC; Rosenberg AE; Yechieli R; Temple HT; Pattany P; Subhawong TK
Front Oncol; 2023; 13():1286807. PubMed ID: 38188297
[TBL] [Abstract][Full Text] [Related]
15. The value of the black fiber sign on T1-weighted images for predicting stability of desmoid fibromatosis managed conservatively.
Murahashi Y; Emori M; Shimizu J; Anzai K; Tanaka T; Naka N; Tsuchie H; Nagasawa H; Miyakoshi N; Shimada Y; Yamashita T
Eur Radiol; 2020 Oct; 30(10):5768-5776. PubMed ID: 32435931
[TBL] [Abstract][Full Text] [Related]
16. Pazopanib therapy for desmoid tumors in adolescent and young adult patients.
Agresta L; Kim H; Turpin BK; Nagarajan R; Plemmons A; Szabo S; Dasgupta R; Sorger JI; Pressey JG
Pediatr Blood Cancer; 2018 Jun; 65(6):e26968. PubMed ID: 29384266
[TBL] [Abstract][Full Text] [Related]
17. Association of MRI T2 Signal Intensity With Desmoid Tumor Progression During Active Observation: A Retrospective Cohort Study.
Cassidy MR; Lefkowitz RA; Long N; Qin LX; Kirane A; Sbaity E; Hameed M; Coit DG; Brennan MF; Singer S; Crago AM
Ann Surg; 2020 Apr; 271(4):748-755. PubMed ID: 30418203
[TBL] [Abstract][Full Text] [Related]
18. Initial Active Surveillance Strategy for Patients with Peripheral Sporadic Primary Desmoid-Type Fibromatosis: A Multicentric Phase II Observational Trial.
Bonvalot S; Cozic N; Le Cesne A; Blay JY; Penel N; Fau M; Chevreau C; Anract P; Waast D; Laurence V; Watson S; Duffaud F; Gouin F; Taieb S; Kind M; Lam L
Ann Surg Oncol; 2023 Dec; 30(13):8653-8659. PubMed ID: 37777684
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic imaging and CEUS findings in a rare case of Desmoid-type fibromatosis. A case report.
Valentino M; Liberatore M; Maghella F; De Soccio V; De Felice C; Messineo D; Drudi FM
J Ultrasound; 2018 Sep; 21(3):253-257. PubMed ID: 29564660
[TBL] [Abstract][Full Text] [Related]
20. Can the MRI signal of aggressive fibromatosis be used to predict its behavior?
Castellazzi G; Vanel D; Le Cesne A; Le Pechoux C; Caillet H; Perona F; Bonvalot S
Eur J Radiol; 2009 Feb; 69(2):222-9. PubMed ID: 19046842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
